--- title: "Globus Medical Inc | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 789.61 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295148355.md" datetime: "2026-08-06T21:38:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295148355.md) - [en](https://longbridge.com/en/news/295148355.md) - [zh-HK](https://longbridge.com/zh-HK/news/295148355.md) generator: "portal-rs" --- # Globus Medical Inc | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 789.61 M Revenue: As of FY2026 Q2, the actual value is USD 789.61 M, beating the estimate of USD 782.98 M. EPS: As of FY2026 Q2, the actual value is USD 1.1, beating the estimate of USD 0.9209. EBIT: As of FY2026 Q2, the actual value is USD 189.82 M. #### Worldwide Net Sales Globus Medical, Inc. reported worldwide net sales of $789.6 million for the second quarter of 2026, marking an increase of 5.9% compared to the second quarter of 2025, or 5.6% on a constant currency basis. U.S. net sales rose by 3.0% to $619.105 million, while international net sales increased by 18.0% to $170.507 million on an as-reported basis, and by 16.2% on a constant currency basis. #### Segment Revenue - **Musculoskeletal Solutions**: Net sales were $763.540 million for the second quarter of 2026, up from $710.182 million in the prior year. For the six months ended June 30, 2026, net sales reached $1,496.524 million, compared to $1,286.115 million for the same period in 2025. - **Enabling Technologies**: Net sales were $26.072 million for the second quarter of 2026, down from $35.160 million in the prior year. For the six months ended June 30, 2026, net sales were $52.942 million, compared to $57.348 million for the same period in 2025. #### Net Income GAAP net income for the second quarter of 2026 was $151.569 million, a decrease of 25.3% from $202.846 million in the second quarter of 2025, primarily due to a bargain purchase gain of $110.5 million recognized in the prior year quarter related to the Nevro acquisition. For the six months ended June 30, 2026, GAAP net income was $275.871 million, slightly down from $278.308 million for the same period in 2025. Non-GAAP net income was $184.294 million for the second quarter of 2026, an increase from $116.782 million in the second quarter of 2025. For the six months ended June 30, 2026, non-GAAP net income was $339.190 million, up from $211.610 million for the same period in 2025. #### Operating Profit and Costs Operating income for the second quarter of 2026 increased to $182.432 million from $76.109 million in the second quarter of 2025. For the six months ended June 30, 2026, operating income was $332.820 million, compared to $173.113 million for the same period in 2025. Operating costs for the second quarter of 2026 included: cost of sales (exclusive of amortization of intangibles) of $241.439 million (2026) versus $248.765 million (2025); research and development of $36.321 million (2026) versus $39.954 million (2025); selling, general and administrative of $286.823 million (2026) versus $303.622 million (2025); amortization of intangibles of $29.560 million (2026) versus $30.189 million (2025); acquisition-related costs of $11.080 million (2026) versus $33.156 million (2025); and restructuring costs of $1.957 million (2026) versus $13.547 million (2025). #### Gross Margin Gross Profit as a percentage of net sales was 66.8% for Q2 2026, compared to 63.3% for Q2 2025. Adjusted Gross Profit as a percentage of net sales was 69.4% for Q2 2026, compared to 67.4% for Q2 2025. #### Adjusted EBITDA Adjusted EBITDA was $279.839 million for the second quarter of 2026, up from $208.682 million in the second quarter of 2025. As a percentage of net sales, Adjusted EBITDA was 35.4% for Q2 2026, compared to 28.0% for Q2 2025. For the six months ended June 30, 2026, Adjusted EBITDA was $525.135 million, compared to $386.515 million for the same period in 2025. #### Cash Flow Net cash provided by operating activities for the six months ended June 30, 2026, was $412.105 million, compared to $255.165 million for the same period in 2025. Free cash flow was $176.574 million for the second quarter of 2026, an increase from $31.303 million in the second quarter of 2025. For the six months ended June 30, 2026, free cash flow was $339.322 million, compared to $172.500 million for the same period in 2025. #### Liquidity As of June 30, 2026, cash and cash equivalents totaled $507.745 million, down from $526.156 million at December 31, 2025. Total cash, cash equivalents, and marketable securities increased to $840.500 million as of June 30, 2026, from $629.062 million at December 31, 2025. #### 2026 Annual Guidance Globus Medical, Inc. reaffirms its full-year 2026 revenue guidance to be in the range of $3.18 billion to $3.22 billion. The company updated its guidance for non-GAAP fully diluted EPS to a range of $4.95 to $5.05, an increase from the previous range of $4.70 to $4.80. ### Related Stocks - [GMED.US](https://longbridge.com/en/quote/GMED.US.md) ## Related News & Research - [Major Insider Move at Globus Medical Shakes Up Investor Sentiment](https://longbridge.com/en/news/296439125.md) - [Globus Medical director Stephen T. Zarrilli disposes of 25,000 common shares worth $2.18 million](https://longbridge.com/en/news/296401521.md) - [Globus Medical, Inc. (NYSE:GMED) Receives Consensus Recommendation of "Moderate Buy" from Analysts](https://longbridge.com/en/news/279001092.md) - [Twist Bioscience (TWST) Is Down 5.1% After Upsized Equity Raise And Guidance Hike Has The Bull Case Changed?](https://longbridge.com/en/news/296070797.md) - [Dicot Pharma submits EU clinical trial application for LIB-01 phase 2b study](https://longbridge.com/en/news/296068059.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**